FOLH1 and posterior cortical atrophy: Theranostic agents such as 177Lu-PSMA-617, 177Lu-PSMA-I&T and 177Lu-iPSMA have demonstrated their ability to efficiently target PSMA-expressing tumors, with the consequent decrease of serum PSA levels in 30–60% of PCa patients5,6.